A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer

Summary

To assess patient preference between ODM-201 and enzalutamide by patient preference questionnaire

Timeline

Start

2017-11-29

Primary completion

2022-01-31

Completion

2024-09-25

Outcome

Missed primary endpoint

paper chose darolutamide, chose enzalutamide, and had no preference, respectively (p = 0.92). PMID 37271630 ↗

paper The study did not show a difference in preference between the two treatments. PMID 37271630 ↗

Publications

• Colomba E, Jonas SF, Eymard JC, Delva R, Brachet PE, Neuzillet Y, Penel N, Roubaud G, Bompas E, Mahammedi H, Longo R, Helissey C, Barthelemy P, Borchiellini D, Hasbini A, Priou F, Saldana C, Voog E, Narcisso B, Ladoire S, Berdah JF, Aisenfarb JB, Foulon S, Fizazi K. A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA. Eur Urol. 2024 Mar;85(3):274-282. doi: 10.1016/j.eururo.2023.05.009. Epub 2023 Jun 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Darolutamide	Other / unclassified	600 mg	—
Comparator	Enzalutamide	Other / unclassified	160 mg	—

Indications